Cell line development strategies towards overcoming multispecific expression challenges
29 Apr 2026
Cell Line Development
- What attributes make multispecific antibodies a promising emerging class of therapeutic modalities?
- How does the structural complexity of multispecific antibodies, typically comprising three or more unique peptide sequences, contribute to manufacturing challenges?
- What are the primary expression-related challenges associated with multispecific antibody production?
- In what ways do product-related impurities arising during multispecific expression impact overall yield, product efficacy, and patient safety?
- Which strategies at the cell line development stage can effectively mitigate the formation of multispecific-related impurities?
- How does balancing transgene expression influence the quality and consistency of multispecific antibody production?
- What key parameters should be considered in the design and optimization of cell line generation processes for multispecific modalities?
- How can advances in cell line development strategies be leveraged to enhance the efficiency and fidelity of multispecific antibody expression?
